TJTinghui Jiang

Tinghui Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tinghui Jiang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical verification of vimentin/EpCAM immunolipid magnetic sorting system in monitoring CTCs in arterial and venous blood of advanced tumor

    by Yan Liu, Qiuying Li, Tingsong Chen, Tianhao Shen, Xufeng Zhang, Ping Song, Lantao Liu, Jianming Liu, Tinghui Jiang, Xiaofei Liang

    Background: Circulating tumor cells (CTCs) are the dominant factor leading to tumor metastasis. This study aims to investigate the effect of disparate sources of CTCs on the treatment and prognosis of patients with advanced tumors by analyzing the number and gene mutations change of CTCs in arterial and venous blood in patients with advanced tumors. Results: A CTCs sorting system was constructed based on Vimentin-immunolipid magnetic balls (Vi-IMB) and EpCAM immunolipid magnetic balls (Ep-IMB). Results showed that the prepared Ep-IMB and Vi-IMB had lower cytotoxicity, better specificity and sensitivity. The number of arterial CTCs was higher than that of venous CTCs, with a statistically significant difference (P < 0.05). Moreover, the prognosis of the low positive group of total CTCs in arterial blood and venous blood was higher than that of the high positive group, with a statistical significance (P < 0.05). The genetic testing results showed that the targeted drug gene mutations in tissues, arterial CTCs and venous CTCs showed a complementary trend, indicating that there was heterogeneity among different tumor samples. Conclusions: CTCs in blood can be efficiently captured by the CTCs sorting system based on Vi-LMB/Ep-LMB, and CTCs detection in arterial blood can be utilized to more accurately evaluate the prognosis and predict postoperative progress. It is further confirmed that tumor samples from disparate sources are heterogeneous, providing a reference basis for gene mutation detection before clinical targeted drug treatment, and the detection of CTCs in arterial blood has more potential clinical application value. Trial registration: The Ethics Committee of Putuo Hospital, PTEC-A-2019-18-1. Registered 24 September 2019. Graphic


  • Icariin inhibits LPS-induced cell inflammatory response by promoting GRα nuclear translocation and upregulating GRα expression

    by Xianjun Sun, Xiaohong Deng, Waijiao Cai, Wenwei Li, Ziyin Shen, Tinghui Jiang, Jianhua Huang


  • Open Access

    MicroRNA-340 Inhibits Esophageal Cancer Cell Growth and Invasion by Targeting Phosphoserine Aminotransferase 1

    by Shuo Yan, Haosheng Jiang, Shiming Fang, Fang Yin, Zhenlei Wang, Yiping Jia, Xianjun Sun, Shaoqiu Wu, Tinghui Jiang, Aiwu Mao

    Background/Aims: Emerging evidence indicates that microRNA (miR)-340 is downregulated in various human cancers, suggesting that it acts as a tumor suppressor. The aim of the present study was to evaluate the expression and role of miR-340 in human esophageal squamous cell carcinoma (ESCC). Methods: The expression of miR-340 was examined in 64 paired ESCC and adjacent non-tumor tissues by quantitative real time PCR. The effects of miR-340 on ESCC cell proliferation and metastasis were examined by MTT and Matrigel invasion assays. Tumor growth was assessed by subcutaneous inoculation of cells into BALB/c nude mice. Targets of miR-340 were identified by bioinformatics and verified by luciferase reporter assays, quantitative real-time PCR, and western blotting. Results: MiR-340 was significantly downregulated in ESCC tumor tissues compared to adjacent non-tumor tissues and in ESCC cell lines compared to esophageal endothelial cells. Overexpression of miR-340 inhibited ESCC cell growth, colony formation, and invasion, and tumor growth in a xenograft mouse model. PSAT1 was identified as a direct target of miR-340 and its ectopic expression partially reversed the miR-340 mediated inhibition of viability, invasion and EMT in ESCC cells. The expression of miR-340 was negatively correlated with that of PSAT1 in human ESCC samples. Conclusion: MiR-340 functions as a tumor suppressor by modulating the expression of PSAT1 and may contribute to the progression and invasiveness of ESCC.


    • 17 June 2014
      • Vol. 94  (23) , 1798-800

    [The study of clinical value of transarterial chemical perfusion as second-line therapy for late stage pancreatic cancer].

    by Chuanlian Jin, Aiwu Mao, Yue Chen, Xianjun Sun, Tinghui Jiang

    To discuss arterial infusion chemotherapy as second-line treatment for advanced pancreatic carcinoma salvage after failed vein chemotherapy. 35 cases with IV stage pancreatic carcinoma, all cases are failed first-line chemotherapy of Gemcitabine. Via femoral artery puncture, gastroduodenal artery, the dorsal pancreatic artery, pancreatic artery, pancreatic tail artery, the rib waist artery, superior mesenteric artery and tumor related to blood supply artery intubation and chemical drug perfusion. Plan: Cisplatin 30 mg/m², Gemcitabine 1 000 mg/m². Treatment for every 3-4 weeks, there is no limit on the total number. 35 cases were local chemotherapy for 217 cycles, at least 1 cycle, a maximum of 9 cycles, 6.2 cycles on average. Among which: CR 1 case, PR 6 cases, SD 15 cases, effective rate (CR+PR) is 20%, disease control rate (DCR) is 68.75%. The median survival time was 9.6 months. The median TTP was 3.7 months. Total effective rate of CBR , the stability rate of CBR and inefficiency rate of CBR were 51.4%, 25.7% and 22.9% respectively. Pain score improvement 88.57% (31/35), 42.86% (15/35) Pain relief last for 3-20 days ( median time 11 days). 17.14% (6/35) Pain relief last for more than 20 days. Pain relief maintain the most elderly 160 days. Half of the patients have different degree of side reaction, III, IV degree leukopenia accounted for 17.14% (6/35), 8.57% (3/35). The arterial perfusion chemotherapy as second-line treatment of advanced pancreatic cancer salvage is of clinical value, with better disease control rate and the rate of pain relief.